Science is often described as a self-correcting enterprise, a system in which weak evidence is challenged, errors are exposed, and truth gradually rises to the surface. Yet in tobacco harm reduction, that ideal increasingly clashes with reality. A growing body of analysis suggests that flawed research not only survives scrutiny but frequently shapes public policy long after its weaknesses are exposed, with serious consequences for smokers seeking safer alternatives.
When science stops self-correcting
A recent critique by the widely acclaimed Arielle Selya PhD, of the harm reduction research landscape, argues that this failure to self-correct is not accidental. Instead, it is driven by distorted funding incentives, intense ideological polarisation, stigma toward researchers perceived to have industry links, and confirmation bias embedded in peer review. While these pressures exist across science, Selya contends they are particularly acute in nicotine research, where moral narratives often override empirical nuance.
In theory, researchers have multiple avenues to challenge problematic studies, explained the critique. They can contact authors directly, submit letters to journal editors, request formal corrections or retractions, or raise concerns on post-publication platforms such as PubPeer. In practice, however, these mechanisms rarely achieve meaningful correction. Retractions are slow and uncommon, letters to editors often favour original authors, and post-publication critiques remain largely invisible to journalists, policymakers, and the public.
The tragedy of inaccurate findings informing policy
An analysis connecting vaping to chronic kidney disease collapsed when a replication study applied more rigorous controls for smoking history and found the association disappeared entirely. Yet the replication struggled to find a publishing outlet and ultimately appeared in a different journal, limiting its ability to correct the original claim.
The damage caused by this inertia is not hypothetical. One high-profile example involved a 2022 study that claimed e-cigarette use increased stroke risk. Independent investigators later uncovered major inconsistencies, including implausible sample sizes, flawed data handling, and questionable author credentials. The paper was eventually retracted, but only after it had already influenced media coverage and public health messaging worldwide. By the time the correction occurred, the narrative had taken root.
Selya highlighted that other cases followed the same trajectory. A systematic review suggesting links between vaping and cancer was challenged for deviating from its protocol, including retracted studies, and reporting inconsistent data. An analysis connecting vaping to chronic kidney disease collapsed when a replication study applied more rigorous controls for smoking history and found the association disappeared entirely. Yet the replication struggled to find a publishing outlet and ultimately appeared in a different journal, limiting its ability to correct the original claim.
This pattern of weak claims gaining traction while corrections languish in obscurity has broader implications, especially as nicotine policy debates intensify across Europe. A recent publication in the European Heart Journal illustrates the problem vividly. Framed as an expert consensus, the report asserted that nicotine itself poses serious cardiovascular risks regardless of delivery method and urged policymakers to restrict all nicotine products equally.
Led by cardiologist Professor Thomas Münzel, the report rejected the concept of “safer nicotine” and recommended sweeping measures, including universal flavour bans, nicotine-based taxation, and tighter marketing controls. While presented as authoritative, critics quickly noted that the document introduced no new empirical data and was authored exclusively by cardiologists, without input from nicotine scientists or harm reduction specialists.
Selectively choosing which “science” to take note of?
Several researchers pushed back against the report’s central premise. Cardiologist Konstantinos Farsalinos warned that “one-risk” messaging erases the substantial difference between combustible cigarettes and non-combustible alternatives, potentially discouraging smokers from switching to products that dramatically reduce harm. Large observational studies, he noted, show improved cardiovascular outcomes among smokers who switch to vaping or quit entirely.
Real-world evidence further complicates the report’s conclusions. Countries where safer nicotine alternatives are widely used, have among the lowest smoking rates globally and have not experienced corresponding increases in cardiovascular disease. Internal medicine specialist Riccardo Polosa has pointed to large cohort studies showing that once confounding factors are accounted for, oral nicotine use is not associated with higher risks of heart attack, heart failure, or cardiovascular mortality. The key driver of harm, he highlights in line with arguments by countless peers, remains combustion, not nicotine itself.
How about ulterior motives?
The timing of the European Heart Journal publication has also raised eyebrows. Consumer advocates such as Damian Sweeney of the European Tobacco Harm Reduction Advocates suggest the report appears designed to influence upcoming EU regulatory and taxation decisions. In that sense, critics argue, it functions less as a balanced scientific review and more as an advocacy document aligned with prohibition-leaning policy agendas.
These concerns echo warnings from within global health institutions themselves. Jindřich Vobořil, a veteran public health and drug policy expert, recently described his experience at the World Health Organization’s COP11 meeting as deeply troubling. According to Vobořil, discussions had drifted away from evidence and toward ideology, with extreme proposals such as criminalising legally operating companies openly entertained.
He found it particularly contradictory that countries with major state-run tobacco interests, including China, supported prohibitionist measures while benefiting domestically from widespread tobacco use and exporting vaping products abroad. Harm reduction advocates and consumer representatives, Vobořil noted, were excluded from the process, while a small group of well-funded NGOs wielded disproportionate influence.
Perhaps most striking was the absence of serious discussion about countries where harm reduction has demonstrably worked. Sweden, the United Kingdom, Japan, and New Zealand have all seen substantial declines in smoking following the adoption of reduced-risk alternatives. Yet these examples were largely ignored in favour of theories long challenged by real-world data.
The consequences of this disconnect are profound. When flawed studies are amplified and corrections sidelined, policy drifts away from evidence. When all nicotine use is portrayed as equally dangerous, smokers are discouraged from switching. And when harm reduction is excluded from global health forums, illicit markets and combustible tobacco use are preserved by default.
Biased science is failing smokers, plocymakers and public health
Against this bleak backdrop, the occasional successful challenge to bad science matters. Retractions, corrections, and critical replications, though rare, demonstrate that persistence can still yield results. They serve as reminders that evidence does matter, even when it is inconvenient.
For tobacco harm reduction to fulfil its potential, science must once again be allowed to correct itself. That means open debate, transparent peer review, inclusion of diverse expertise, and policies grounded in relative risk rather than ideology. The alternative, as history increasingly shows, is not safety, but stagnation—and a preventable continuation of smoking-related disease.
